Loading…

Inhaled Fasudil Lacks Pulmonary Selectivity in Thromboxane-Induced Acute Pulmonary Hypertension in Newborn Lambs

Introduction: Pulmonary hypertension (PH) is a potentially deadly disease for infants and adults with few existing medical interventions and no cure. In PH, increased blood pressure in the pulmonary artery eventually leads to heart failure. Fasudil, an antagonist of Rho-kinase, causes vasodilation l...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cardiovascular pharmacology and therapeutics 2018-09, Vol.23 (5), p.472-480
Main Authors: Hanson, Shawn F. L., Terry, Michael H., Moretta, Dafne T., Power, Gordon G., Wilson, Sean M., Alam, Farzana, Ahsan, Fakhrul, Blood, Arlin B., Giri, Paresh C.
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: Pulmonary hypertension (PH) is a potentially deadly disease for infants and adults with few existing medical interventions and no cure. In PH, increased blood pressure in the pulmonary artery eventually leads to heart failure. Fasudil, an antagonist of Rho-kinase, causes vasodilation leading to decreased systemic artery pressure and pulmonary artery pressure (PAP). This study compared the effects of fasudil administered as either an intravenous infusion or inhaled aerosol in newborn lambs. Hypothesis: Inhaled aerosol delivery of fasudil will provide selective pulmonary vasodilation when compared with intravenous administration. Methods: Newborn lambs (∼11 days) were surgically instrumented and mechanically ventilated under anesthesia. A pulmonary artery catheter and ultrasonic flow probe were inserted to measure hemodynamics. Acute PH was pharmaceutically induced via continuous intravenous infusion of thromboxane. After achieving a 2- to 3-fold elevation of PAP, fasudil was administered either as intravenous infusion (2.5 mg/kg) or inhaled aerosol (100 mg of fasudil in 2 mL of saline). Changes in PAP, mean systemic arterial pressure (MABP), pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), cardiac output, and heart rate were assessed. In addition, plasma concentrations of fasudil were measured. Results: Both routes of fasudil delivery produced significant decreases in PAP and PVR but also produced similar decreases in MABP and SVR. The Cmax for intravenous fasudil was greater than that for inhaled fasudil. Conclusions: These results suggest inhaled fasudil lacks pulmonary selectivity when compared with intravenous fasudil.
ISSN:1074-2484
1940-4034
DOI:10.1177/1074248418772814